Robert Schultz

Prior to joining Satsuma Pharmaceuticals, Rob was an early member of the senior leadership team at Pearl Therapeutics (acquired by AstraZeneca), where he led CMC and global project teams developing Pearl’s metered-dose inhaler (MDI) products, including Bevespi Aerosphere and Pearl’s triple combination MDI.  Since entering the pharmaceutical industry in 1989, Rob has also led CMC development initiatives for multiple other inhalation products, including Advair, Serevent, Flovent, Ventolin, Azmacort, and an insulin MDI product, while serving in roles of increasing responsibility at GlaxoSmithKline and at Kos (acquired by Abbott).  Rob earned his biochemistry degree from Dartmouth College.